SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: January
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -3.13
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.22

24 May
2024

0.000

OPEN

$1.20

0.000

HIGH

$1.22

5,023,584

LOW

$1.20

TARGET
$1.057 -13.4% downside
Franking for last dividend paid out: 50%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx N/A 1.6 xxx
DPS (cps) xxx N/A 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 74.5 xxx
Dividend Yield xxx N/A 0.8% xxx
Div Pay Ratio(%) xxx N/A 60.1% xxx

Dividend yield today if purchased 3 years ago: 1.52%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.81

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.4
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx3,322.1 M
Book Value Per Share xxxxxxxxxxxxxxx55.4
Net Operating Cash Flow xxxxxxxxxxxxxxx42.0 M
Net Profit Margin xxxxxxxxxxxxxxx0.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx0.67 %
Return on Invested Capital xxxxxxxxxxxxxxx0.53 %
Return on Assets xxxxxxxxxxxxxxx0.35 %
Return on Equity xxxxxxxxxxxxxxx0.67 %
Return on Total Capital xxxxxxxxxxxxxxx-8.40 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx27.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx10 M
Long Term Debt xxxxxxxxxxxxxxx127 M
Total Debt xxxxxxxxxxxxxxx137 M
Goodwill - Gross xxxxxxxxxxxxxxx89 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx356 M
Price To Book Value xxxxxxxxxxxxxxx1.87

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.7 M
Capex % of Sales xxxxxxxxxxxxxxx0.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,132 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx262 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx14 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Shaw and Partners

xx/xx/xxxx

5

xxxxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

22/03/2024

5

Underperform

$0.90

-26.23%

Macquarie considers FY24 results by Sigma Healthcare were largely a sideshow when set against the ongoing reverse takeover by Chemist Warehouse Group.

Profit of $4.7m on $3.3bn of sales is indicative of tight margins in the legacy business, suggests the analyst. Management reaffirmed its medium-term earnings (EBIT) margin target of 1.5-2.5% on a standalone basis for the Sigma business.

The Chemist Warehouse business had a very strong first half, in the broker's opinion, with earnings of $324m and profit of $360m due to a one-off tax benefit.

The target rises to 90c form 88c and the Underperform rating is unchanged.

FORECAST
Macquarie forecasts a full year FY25 dividend of 1.80 cents and EPS of 3.50 cents.
Macquarie forecasts a full year FY26 dividend of 2.40 cents and EPS of 4.70 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SIG STOCK CHART